Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications... Show more
Apogee Therapeutics shares no longer trade on the Nasdaq. The stock's last completed session occurred on September 2, 2026, closing at $135.07, essentially in line with the $135.11 per-share cash consideration paid to shareholders at closing. Over its final 30 calendar days of trading, the share price drifted only modestly—from about $134.11 on August 3 to $135.07 on September 2—a move of less than 1%, as the market priced the stock near the takeover value pending completion.
For context, APGE traded in a 52-week range of $35.39 to $135.09. The climb from the low end of that range reflects a year in which strong clinical data and, ultimately, a definitive acquisition agreement re-rated the stock significantly.
Apogee Therapeutics is a clinical-stage biotechnology company that develops optimized antibody-based therapies for inflammatory and immunology (I&I) diseases, including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. Founded in 2022 and headquartered in San Francisco with an office in the Boston area, the company built its platform around antibody engineering designed to extend half-life and reduce dosing frequency relative to existing standards of care.
Its lead asset, zumilokibart (APG777), is a half-life-extended monoclonal antibody targeting interleukin-13 (IL-13), initially developed for atopic dermatitis and expanding into asthma and eosinophilic esophagitis. Apogee's broader "pipeline-in-a-product" strategy also included APG990 (targeting OX40L), APG333 (targeting TSLP), APG808 (targeting IL-4Rα), and the combination candidates APG279 and APG273.
The dominant catalyst behind APGE's trajectory was its acquisition by AbbVie. In June 2026, AbbVie announced a definitive agreement to acquire all outstanding Apogee shares for $135.11 per share in cash, a roughly 49% premium to the prior close of $90.38. Apogee shareholders approved the merger at a special meeting on August 11, 2026, and the transaction closed on September 3, 2026, after which the stock ceased trading on Nasdaq.
Prior to the buyout, Apogee had been advancing its pipeline through a series of milestones. In its full-year 2025 results, the company reported a net loss of $255.8 million, widened from $182.1 million in 2024, and ended the year with $902.9 million in cash, cash equivalents, and marketable securities. The company also disclosed a $1.3 billion strategic financing collaboration with Blackstone Life Sciences intended to support Phase 3 development and potential commercialization of zumilokibart. Interim results from the APEX Phase 2 trial and a Phase 1b asthma study had reinforced confidence in the lead program, contributing to the strategic value recognized in the acquisition.
For traders seeking a data-driven approach to market analysis, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section, which is refreshed based on recent performance and market conditions. These bots vary in strategy, timeframe, and performance metrics, so the page can serve as a useful starting point for comparing different automated approaches. Exploring the current lineup may help you identify tools aligned with your own trading style and objectives.
Because Apogee has been acquired and delisted, former shareholders received cash consideration and no longer hold APGE shares. For those following the underlying assets, the relevant developments now sit within AbbVie, which plans to advance zumilokibart toward Phase 3 in atopic dermatitis and continue development across respiratory and other inflammatory indications. AbbVie has indicated the acquisition is expected to reduce its adjusted diluted earnings per share by $0.14 in 2026 and approximately $0.46 in 2027, with the transaction expected to become accretive beginning in 2032.
Investors tracking the story may wish to monitor subsequent clinical data readouts for zumilokibart, regulatory progress, and AbbVie's integration of the Apogee pipeline. As always, individual outcomes remain subject to clinical, regulatory, and commercial risk.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry Biotechnology